T2 Biosystems

T2 Biosystems, Inc. engages in the development of a proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types. The firm's products include the T2Dx Instrument, the T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

T2 Biosystems reports revenue growth, eyes FDA breakthroughs for expansion

T2 Biosystems demonstrated strong revenue growth and operational improvements in Q3 2024, driven by sepsis test panel sales and strategic partnerships.
While facing financial challenges and regulatory complexities, the company's focus on innovation and market expansion presents significant opportunities for future growth.
Overall, T2 Biosystems remains optimistic about its growth prospects, supported by advancements in its product pipeline and collaborations to combat healthcare challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Achieved record sepsis product revenue and sepsis-driven T2Dx Instrument units in 2022 Achieved record sepsis product revenue and sepsis-driven T2Dx Instrument units in 2022

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results

LEXINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its Innovative Technology contract with Vizient, Inc., the largest member-driven health care performance improvement company in the country, has been extended through March 31, 2024. The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bacteria® Panel and the T2Candida® Panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood.

T2 Biosystems Announces Extension of Multiyear Innovative Technology Contract with Vizient, Inc.

LEXINGTON, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the publication of a peer-reviewed article published by Oxford University Press on behalf of the Infectious Diseases Society of America.

T2 Biosystems Highlights Peer-Reviewed Article Linking COVID-19 and Sepsis and Underscoring CDC Call for Adoption of Early and Accurate Microbial Diagnosis to Guide Targeted Initial Antimicrobial Therapy

T2 Biosystems, Inc. (NASDAQ:TTOO ) Q3 2022 Results Conference Call November 10, 2022 4:30 PM ET Company Participants Emma Poalillo - IR, Gilmartin Group John Sperzel - Chairman, CEO John Sprague - CFO Brett Giffin - CCO Conference Call Participants Kyle Mikson - Canaccord Vidyun Bais - BTIG Steve Brozak - WBB Operator Ladies and gentlemen, welcome to the T2 Biosystems Incorporated Third Quarter 2022 Earnings Conference Call. Your host for today, Emma Poalillo.

T2 Biosystems, Inc. (TTOO) Q3 2022 Earnings Call Transcript

Achieves record quarterly sepsis and related revenue and advances product pipeline Achieves record quarterly sepsis and related revenue and advances product pipeline

T2 Biosystems Announces Third Quarter 2022 Financial Results

LEXINGTON, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the U.S. Department of Health and Human Services (“HHS”) and the Steven & Alexandra Cohen Foundation (“Cohen Foundation”) have selected T2 Biosystems as a Phase 1 winner in the LymeX Diagnostics Prize, a LymeX Innovation Accelerator (“LymeX”) prize competition to accelerate the development of Lyme disease diagnostics. As a Phase 1 winner, T2 Biosystems will receive $100,000 and an invitation to participate in a second phase.

HHS and the Cohen Foundation Name T2 Biosystems a Phase 1 Winner in LymeX Diagnostics Prize

LEXINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on October 31, 2022 informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market.

T2 Biosystems Regains Compliance with Nasdaq's Minimum Bid Price Rule

LEXINGTON, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2022 after market close on Thursday, November 10, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

T2 Biosystems to Report Third Quarter 2022 Financial Results on November 10, 2022

LEXINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has initiated studies to expand the number of pathogens detected on the FDA-cleared T2Bacteria® Panel to include the detection of Acinetobacter baumannii.

T2 Biosystems Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel

Studies demonstrate that T2Bacteria and T2Candida panels enable sensitive and specific diagnosis to enhance the standard of care Studies demonstrate that T2Bacteria and T2Candida panels enable sensitive and specific diagnosis to enhance the standard of care

T2 Biosystems Highlights Multiple New Studies Demonstrating Improved Rapid Detection Across Several Patient Populations

A 1-for-50 reverse split of T2 Biosystems (TTOO) shares went into effect today.  The post T2 Biosystems (TTOO) Stock: 1-For-50 Reverse Split Goes Into Effect appeared first on Pulse 2.0.

T2 Biosystems (TTOO) Stock: 1-For-50 Reverse Split Goes Into Effect

Plans to Initiate Marketing and Sales in the U.S. as a Laboratory Developed Test in 2023 Plans to Initiate Marketing and Sales in the U.S. as a Laboratory Developed Test in 2023

T2 Biosystems Announces Plan to Commercialize a Diagnostic Test for Early Lyme Disease

LEXINGTON, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial results for the third quarter ended September 30, 2022.

T2 Biosystems Announces Preliminary Third Quarter 2022 Financial Results and Updates 2022 Financial Outlook

Advances U.S. Clinical Trials and FDA Submission for T2Resistance and T2Biothreat Panels Advances U.S. Clinical Trials and FDA Submission for T2Resistance and T2Biothreat Panels

T2 Biosystems Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million

T2 Biosystems (NASDAQ: TTOO ) stock got a 23% boost overnight after it announced a distribution agreement covering the Baltics. T2 makes test kits for detecting sepsis.

What Is Going on With T2 Biosystems (TTOO) Stock Today?

LEXINGTON, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in the Baltic Region, including Lithuania, Latvia, and Estonia. Under the terms of the agreement, T2 Biosystems will sell T2Dx® Instruments, along with T2Bacteria®, T2Candida® and T2Resistance® Panels through the distributor.

T2 Biosystems Announces Commercial Expansion Through Distributor in Baltic Region

LEXINGTON, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming H.C. Wainwright Global Investment Conference in New York, New York.

T2 Biosystems to Participate in the H.C. Wainwright Global Investment Conference

Clarus Therapeutics Holdings

Palisade Bio

Timber Pharmaceuticals

Penny stocks under $1 to watch this week. The post Top Penny Stocks To Buy?

Top Penny Stocks To Buy? 4 For Your Watch List Before Next Week

LEXINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to present on Wednesday, August 31, 2022, at 11:30am ET.

T2 Biosystems to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

T2 Biosystems, Inc. (NASDAQ:TTOO ) CEO Q2 2022 Results Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Emma Poalillo - Investor Relations, Gilmartin Group John Sperzel - Chairman and Chief Executive Officer John Sprague - Chief Financial Officer Conference Call Participants Stephen Brozak - WBB Securities Operator Good day and welcome to T2 Biosystems Second Quarter 2022 Earnings Conference Call. All participants are in listen-only mode.

T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q2 2022 Results - Earnings Call Transcript

T2Dx Instrument contracts increased by 300% compared to the prior year period T2Dx Instrument contracts increased by 300% compared to the prior year period

T2 Biosystems Announces Second Quarter 2022 Financial Results

FuboTV

SmileDirectClub

Here's what you need to know about buying penny stocks on August 12th, 2022 The post Best Penny Stocks to Buy As Inflation Drops, 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy As Inflation Drops, 3 to Watch

Helbiz

Invitae

Here's what you need to know about trading penny stocks on August 11th The post Popular Penny Stocks to Watch as the Bear Market Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Popular Penny Stocks to Watch as the Bear Market Ends

Source: Viacheslav Lopatin / Shutterstock.com T2 Biosystems (NASDAQ: TTOO ) stock is getting a boost on Wednesday after announcing plans to investigate monkeypox tests. According to a press release from the in vitro diagnostics company, it's weighing the viability of developing a rapid molecular diagnostic test for the monkeypox virus.

T2 Biosystems (TTOO) Stock Gains on Monkeypox Test News

Endo International

Here's what you need to know about trading penny stocks on August 10th The post Best Penny Stocks to Buy Now? 3 For Your August List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for T2 Biosystems Stock (TTOO)